93 filings
8-K
ENTA
Enanta Pharmaceuticals Inc
12 Mar 24
Departure of Directors or Certain Officers
4:00pm
8-K
ENTA
Enanta Pharmaceuticals Inc
7 Feb 24
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
4:05pm
8-K
ENTA
Enanta Pharmaceuticals Inc
26 Dec 23
Departure of Directors or Certain Officers
4:06pm
8-K
ENTA
Enanta Pharmaceuticals Inc
20 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
ENTA
Enanta Pharmaceuticals Inc
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
a860dn fua5
7 Jun 23
Regulation FD Disclosure
7:01am
8-K
nsvda07ffkla38y1xu7
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm
8-K
xobagqcvplqbtuoa
27 Apr 23
Non-Dilutive and Strengthens Balance Sheet
4:43pm
8-K
z65yed xt
10 Mar 23
Regulation FD Disclosure
4:43pm
8-K
maur 172ioem988
7 Mar 23
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
repyhi
7 Feb 23
Results of Operations and Financial Condition
4:06pm
8-K
wftga
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
24ekvd 1vyd
26 Aug 22
Entry into a Material Definitive Agreement
4:10pm
8-K
wd78c
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
x8lr qm1at
22 Jun 22
Other Events
6:22am
8-K
2j3lfst
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
iakitblatdj1
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm
8-K
4jnpu6ra4t aduv
9 Mar 22
Departure of Directors or Certain Officers
4:03pm
8-K
clj5rlwlrbive
8 Mar 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
gkntkej0 ynxije86
8 Feb 22
Results of Operations and Financial Condition
1:44pm